LakeShore Biopharma (LSB) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LakeShore Biopharma has reported a rise in gross margin to 79.5% for Fiscal Year 2024, despite a decrease in revenue due to supply chain issues impacting their rabies vaccine production. The company has successfully resolved inventory challenges and anticipates double-digit revenue growth with a breakeven bottom line for Fiscal Year 2025. Advances in their product pipeline, including the PIKA rabies vaccine and other biologics for infectious diseases and cancer, are also highlighted as part of LakeShore’s strategic focus on innovation and shareholder value.
For further insights into LSB stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue